The pituitary has two separate doors for releasing growth hormone. One opens with GHRH. The other opens with ghrelin. Understanding both pathways explains why certain peptides are studied alone — and why others are studied together.
Two Receptors, Two Cascades
Growth hormone (GH) is released by pituitary cells called somatotrophs. Those cells carry two main receptors that trigger GH release.
The first is the GHRH receptor. GHRH stands for growth hormone-releasing hormone, the natural signal from the hypothalamus. When GHRH binds, the cell makes cyclic AMP (cAMP), which activates protein kinase A (PKA). That cascade drives GH release.
The second is GHS-R1a, the ghrelin receptor. Ghrelin is a hormone made mostly in the stomach. When it binds GHS-R1a, a different cascade fires — one based on inositol trisphosphate (IP3) and calcium release inside the cell.
Two doors. Two different keys. Same end result: more GH released into the bloodstream (Howard et al., 1996).
Which Peptides Hit Which Door
Researchers can target each pathway separately. CJC-1295 and Tesamorelin are GHRH analogs. They bind the GHRH receptor and trigger the cAMP/PKA pathway, mimicking the body's natural signal.
Ipamorelin and MK-677 are different. They are ghrelin-receptor agonists. MK-677 is an oral small molecule. Ipamorelin is an injectable peptide. Both engage GHS-R1a and the IP3/calcium cascade.
Studied alone, each compound exercises one of the two pathways. That is useful for isolating mechanisms.
Why Combinations Are Studied
Activating only one receptor is like opening one door. Activating both is like opening two. The signals add together rather than fight each other (Bowers, 2001).
This is the logic behind studying CJC-1295 with Ipamorelin. CJC-1295 hits the GHRH receptor. Ipamorelin hits GHS-R1a. The two cascades — cAMP/PKA and IP3/calcium — converge on GH release through different routes.
Researchers see additive GH output, not competitive blocking. The somatotroph has both doors open at once.
Why Selectivity Matters
Not all ghrelin-receptor agonists are equal. Older compounds like GHRP-6 stimulate GH release, but they also raise cortisol and prolactin and increase appetite signals (Bowers et al., 1991).
That makes their data harder to interpret. If GH goes up but cortisol also rises, downstream effects are mixed. The signal is dirty.
Ipamorelin was developed to be more selective. In published studies, it stimulates GH without meaningfully raising cortisol or prolactin (Raun et al., 1998). That cleaner profile is why it has become the standard ghrelin-pathway peptide in current research.
For research design, selectivity translates to interpretability. Cleaner inputs give cleaner outputs.
Plenty of questions remain. How does long-term dual-pathway activation affect receptor density and feedback loops? Are there real differences between oral GHS-R agonists like MK-677 and injectable peptides like Ipamorelin beyond pharmacokinetics? These compounds are sold strictly for in vitro laboratory research and are not approved for human consumption.